DSG2 and cancer: Abnormally high expression of DSG2 is closely associated with poor prognosis in multiple types of cancer, including skin cancer [18], colon cancer [19], non-small cell lung cancer [20], lung adenocarcinoma [21,22], stomach cancer [23], breast cancer [24], and hepatocellular cancer [25], making it an appealing candidate serum biomarker for certain tumors.